In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We ...

Convergence processes are based on the activity of distinct industry sectors showing crossindustry collaborations. The aim of this paper is to analyze cross-industry collaborations between the food and pharmaceutical sectors in the convergence area of functional foods. Selected companies from food (Nestlé/Danone) and pharmaceutical (Martek/Bayer HealthCare) sectors are analyzed using the determ...

BACKGROUND Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical companies' perspective was explored with a focus on the number of e...

Stakeholders in healthcare are increasingly turning to real world evidence (RWE) to inform their decisions, alongside evidence from randomized controlled trials. RWE is generated by analysing data gathered from routine clinical practice, and can be used across the product lifecycle, providing insights into areas including disease epidemiology, treatment effectiveness and safety, and health econ...

Venture capital companies play an important role in the economy of countries and greatly influences economic and employment growth. VC is the provision of capital for companies and entrepreneurs that is prone to leaping and growing value and, of course, a lot of risk. However, the volume of venture capital in our country is far less than the economic capacity. Many of analysts consider having n...

This paper analyzes the changing R&D process at Japanese pharmaceutical companies, based on a questionnaire survey as well as structured interviews at large Japanese pharmaceutical companies. Japanese pharmaceutical companies have recently engaged in active R&D collaborations with other firms as well as universities. This paper identifies the factors underlying this trend, finding that all thre...

Achieving increased access to medicines in low- and middle-income countries is a complex issue that requires a holistic approach. Choosing an appropriate manufacturing strategy that can ensure a sustainable supply of these medicines is an essential component of that approach. The Chlorhexidine Working Group, a consortium of more than 25 international organizations, donors, and manufacturers led...

Unlike the health of our bodies, the health of our minds is often neglected. In 2007, The Lancet’s Series on Global Mental Health sought to draw attention to the worldwide burden of mental illness. Data published by Michael Phillips and colleagues in this issue indicate that mental health disorders might aff ect far more people than previously estimated. Their study took on the challeng ing tas...

Since 2004, the Subcommittee for Development of the National List of Essential Drugs (NLED) has embarked upon an historical evolution of applying evidence to the revision, inclusion and exclusion of medicines into and from the list. Then, the revision of the 2008 NLED was the first time in Thai history where the drug selection process in Thailand formally incorporated pharmacoeconomics. At pres...